Compared with the standard immune biomarkers like PD‐L1, TMB, and MSI‐H, which are assessed before treatment, longitudinal assessment of ctDNA dynamics provides an accessible view into tumor response to therapy, as seen by the correlation between changes in ctDNA levels from baseline to time‐matched changes in tumor sum of the longest diameter measurements (Fig. S5B). This evidence concerns the gene CD274 and neoplasm.